FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308126629> ?p ?o ?g. }

• W4308126629 endingPage "1848" @default.
• W4308126629 startingPage "1848" @default.
• W4308126629 abstract "Leishmaniasis is a widespread vector-borne disease in Brazil, with Leishmania (Leishmania) infantum as the primary etiological agent of visceral leishmaniasis (VL). Dogs are considered the main reservoir of this parasite, whose treatment in Brazil is restricted to the use of veterinary medicines, which do not promote a parasitological cure. Therefore, efficient vaccine development is the best approach to Canine Visceral Leishmaniasis (CVL) control. With this in mind, this study used hamsters (Mesocricetus auratus) as an experimental model in an anti-Leishmania preclinical vaccine trial to evaluate the safety, antigenicity, humoral response, and effects on tissue parasite load. Two novel formulations of nanoparticles made from poly(D, L-lactic) acid (PLA) polymer loading Leishmania braziliensis crude antigen (LB) exhibiting two different particle sizes were utilized: LBPSmG (570 nm) and LBPSmP (388 nm). The results showed that the nanoparticles were safe and harmless to hamsters and were antigenic with the induction in LBSap, LBPSmG, and LBPSmG groups of total anti-Leishmania IgG antibodies 30 days after challenge, which persists 200 days in LBSap and LBPSmP. At the same time, a less pronounced hepatosplenomegaly in LBSap, LBPSmG, and LBPSmP was found when compared to control groups, as well as a less pronounced inflammatory infiltrate and granuloma formation in the spleen. Furthermore, significant reductions of 84%, 81%, and 90% were observed in spleen parasite burden accessed by qPCR in the LBSap, LBPSmG, and LBPSmP groups, respectively. In this way, LBSap, LBPSmG, and LBPSmP formulations showed better results in vaccinated and L. infantum-challenged animals in further reducing parasitic load in the spleen and attenuating lesions in liver and splenic tissues. This results in safe, harmless nanoformulation vaccines with significant immunogenic and infection control potential. In addition, animals vaccinated with LBPSmP had an overall reduction in parasite burden in the spleen, indicating that a smaller nanoparticle could be more efficient in targeting antigen-presenting cells." @default.
• W4308126629 created "2022-11-08" @default.
• W4308126629 creator A5005281876 @default.
• W4308126629 creator A5006537651 @default.
• W4308126629 creator A5014878161 @default.
• W4308126629 creator A5017523406 @default.
• W4308126629 creator A5017541421 @default.
• W4308126629 creator A5018472163 @default.
• W4308126629 creator A5020213636 @default.
• W4308126629 creator A5021261782 @default.
• W4308126629 creator A5021826128 @default.
• W4308126629 creator A5028575234 @default.
• W4308126629 creator A5044067781 @default.
• W4308126629 creator A5049302016 @default.
• W4308126629 creator A5051587813 @default.
• W4308126629 creator A5053127019 @default.
• W4308126629 creator A5062091708 @default.
• W4308126629 creator A5063528242 @default.
• W4308126629 creator A5070084843 @default.
• W4308126629 creator A5071852392 @default.
• W4308126629 creator A5073088963 @default.
• W4308126629 creator A5084954729 @default.
• W4308126629 date "2022-10-31" @default.
• W4308126629 modified "2023-09-26" @default.
• W4308126629 title "Nanoformulations with Leishmania braziliensis Antigens Triggered Controlled Parasite Burden in Vaccinated Golden Hamster (Mesocricetus auratus) against Visceral Leishmaniasis" @default.
• W4308126629 cites W1483088720 @default.
• W4308126629 cites W1528348540 @default.
• W4308126629 cites W1649418318 @default.
• W4308126629 cites W1752411429 @default.
• W4308126629 cites W1964580662 @default.
• W4308126629 cites W1964846818 @default.
• W4308126629 cites W1969234492 @default.
• W4308126629 cites W1971413150 @default.
• W4308126629 cites W1973536513 @default.
• W4308126629 cites W1977630790 @default.
• W4308126629 cites W1994879603 @default.
• W4308126629 cites W1998150930 @default.
• W4308126629 cites W2002038646 @default.
• W4308126629 cites W2010024741 @default.
• W4308126629 cites W2026225923 @default.
• W4308126629 cites W2044605934 @default.
• W4308126629 cites W2060584630 @default.
• W4308126629 cites W2070385394 @default.
• W4308126629 cites W2081067297 @default.
• W4308126629 cites W2081120625 @default.
• W4308126629 cites W2082772729 @default.
• W4308126629 cites W2090092365 @default.
• W4308126629 cites W2097371306 @default.
• W4308126629 cites W2107255267 @default.
• W4308126629 cites W2118097105 @default.
• W4308126629 cites W2122510929 @default.
• W4308126629 cites W2128934286 @default.
• W4308126629 cites W2131977263 @default.
• W4308126629 cites W2138562734 @default.
• W4308126629 cites W2139224712 @default.
• W4308126629 cites W2140056038 @default.
• W4308126629 cites W2144907950 @default.
• W4308126629 cites W2151545331 @default.
• W4308126629 cites W2169682500 @default.
• W4308126629 cites W2215373933 @default.
• W4308126629 cites W2239354855 @default.
• W4308126629 cites W2314409564 @default.
• W4308126629 cites W2516980192 @default.
• W4308126629 cites W2575471090 @default.
• W4308126629 cites W2592869913 @default.
• W4308126629 cites W2896396873 @default.
• W4308126629 cites W2901292332 @default.
• W4308126629 cites W2907435368 @default.
• W4308126629 cites W2939883892 @default.
• W4308126629 cites W2976149320 @default.
• W4308126629 cites W3028196259 @default.
• W4308126629 cites W3106119424 @default.
• W4308126629 cites W337551223 @default.
• W4308126629 cites W4225153228 @default.
• W4308126629 cites W4282829565 @default.
• W4308126629 doi "https://doi.org/10.3390/vaccines10111848" @default.
• W4308126629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36366357" @default.
• W4308126629 hasPublicationYear "2022" @default.
• W4308126629 type Work @default.
• W4308126629 citedByCount "2" @default.
• W4308126629 countsByYear W43081266292023 @default.
• W4308126629 crossrefType "journal-article" @default.
• W4308126629 hasAuthorship W4308126629A5005281876 @default.
• W4308126629 hasAuthorship W4308126629A5006537651 @default.
• W4308126629 hasAuthorship W4308126629A5014878161 @default.
• W4308126629 hasAuthorship W4308126629A5017523406 @default.
• W4308126629 hasAuthorship W4308126629A5017541421 @default.
• W4308126629 hasAuthorship W4308126629A5018472163 @default.
• W4308126629 hasAuthorship W4308126629A5020213636 @default.
• W4308126629 hasAuthorship W4308126629A5021261782 @default.
• W4308126629 hasAuthorship W4308126629A5021826128 @default.
• W4308126629 hasAuthorship W4308126629A5028575234 @default.
• W4308126629 hasAuthorship W4308126629A5044067781 @default.
• W4308126629 hasAuthorship W4308126629A5049302016 @default.
• W4308126629 hasAuthorship W4308126629A5051587813 @default.
• W4308126629 hasAuthorship W4308126629A5053127019 @default.
• W4308126629 hasAuthorship W4308126629A5062091708 @default.
• W4308126629 hasAuthorship W4308126629A5063528242 @default.

• next